Congress ReportsArchives
KCA Consensus Statement: RCC digital pathology and molecular diagnostics (Proceedings of the 2024 IKCS: Europe Symposium )
Congress Reports 1 min.
Dr James Blackmur (Cambridge University Hospital NHS Foundation Trust, UK) investigated the current state of practice and produced a consensus statement with regard to digital pathology, molecular diagnostics, and biobanking for renal cancer [1]. They invited participants to the Kidney Cancer Association...
Real-world sarcomatoid metastatic RCC data from the UK ROC (Proceedings of the 2024 IKCS: Europe Symposium)
Congress Reports 1 min.
In the renal oncology community, it is thought that patients with sarcomatoid changes should be treated with immuno-oncology (IO) instead of tyrosine kinase inhibitors (TKI). In fact, according to data of the Checkmate 214 trial, ipilimumab plus nivolumab (IO/IO) is the preferred standard of care for...
Bone response in renal cell carcinoma in the first-line setting (Proceedings of the 2024 IKCS: Europe Symposium )
Congress Reports 1 min.
The arrival of immune checkpoint inhibitors (ICI) has improved the outcomes for patients with metastatic renal cell carcinoma (RCC). However, the evidence with respect to the effect of ICI-based therapies on bone metastases, a poor prognostic factor in RCC, is scarce. Since bone metastases occur in about...
